Pharmacotherapeutic Group: A protease with anti-inflammatory activity.
Pharmacology: Serratiopeptidase improves aggravated circulation in the inflammatory focus by breaking down abnormal exudates and protein and by promoting the absorption of the decomposed products through the blood and lymphatic vessels. It also accelerates the elimination of sputum, pus and haematoma by breaking down the liquifying mucus secretions and fibrin clots. Another major useful action being increased concentration of antibiotics in the focus of infection.
Pharmacokinetics: Serratiopeptidase is absorbed orally as an intact molecule. Some amount of the orally administered Serratiopeptidase is transferred to blood stream in a catalytically active form. Significant amounts are absorbed through the lymphatic channels. In the blood Serratiopeptidase is complexed by α2-macroglobulin as an inclusion complex which leaves the active sites accessible.
It is known to penetrate into inflamed tissue but the time frames for the action are not known.